Avectas
Avectas is a cell engineering technology company that enables drug developers to manufacture potent engineered cell therapies.
Total raised
€27M
€27,019,800
Funding rounds
2
Investors
1
distinct backers
Active since
2019-03
latest 2020-04
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood25
base rate 51% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▲ High-conviction backers
Exit likelihood15
base rate 12% (2+ rounds)
- ▲ 16y since founding
- ▲ High-conviction backers
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-04-16 | Series C | €18M | Seamus Mulligan | View deal → |
| 2019-04-01 | Other | €8.6M | Seamus Mulligan | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Wayflyer€2.1BIreland · E-commerce
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Oura Health€779MFinland · Healthtech